Generex Biotechnology to Make Podium Presentation at the World Congress on Controversies in Obesity, Diabetes and Hypertension
Thursday October 26, 11:15 am ET
TORONTO--(MARKET WIRE)--Oct 26, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs, will make a podium presentation at The World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) (www.codhy.com) to be held in Berlin, Germany, October 26 - 29, 2006. The presentation relates to clinical studies in respect of Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product designed to replace prandial insulin injections.
ADVERTISEMENT
On October 27, 2006, Dr. Bernstein will present a paper entitled "3-Month Interim Results (6-Month Study) on Safety and Efficacy of an Oral Insulin (Generex Oral-lyn(TM)) Administered at Lunchtime in Juvenile Type-1 Diabetes Mellitus Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin." The paper was co-authored by Drs. Jaime Guevara-Aguirre, Marco Guevara-Aguirre and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR in Quito, Ecuador.
In addition, the following Generex-sponsored study is the subject of a poster presentation at CODHy: "Generex Metformin Gum: An Alternative Method for Delivery of Biguanides," authored by Drs. Jaime Guevara-Aguirre, David Saldarreaga, Marco Guevara-Aguirre, and Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito, Ecuador, and Dr. Gerald Bernstein, the Company's Vice-President - Medical Affairs.
Generex is also pleased to announce that Dr. Jaime Davidson, its Medical Director, will be participating in a pre-congress symposium on October 26, 2006 entitled "New Concepts in the Management of Type-2 Diabetes: a DPP-4 Inhibitor Pre-Symposium." Dr. Davidson will be making the symposium introduction with a talk entitled "Key Limitations in the Current Therapies for Type-2 Diabetes." Dr. Davidson will also be making the following additional presentations at CODHy: "Glycemic Targets in Clinical Practice: What should be the focus?," "Confronting Diabetes: The coronary heart disease (CHD) risk equivalent," and "Debate: Insulin analogues versus pump therapy in Type-2 Diabetes."
This congress will be focusing on two significant aspects of diabetes management which are the focus of the Generex product pipeline: prevention, and post-prandial glucose control.
The strong connection between obesity, diabetes, and hypertension is well recognized by the medical community yet their treatments were for many years unrelated. With all three conditions having reached epidemic proportions worldwide, their treatments as one field are now rapidly expanding. CODHy is an exclusive forum in which world eminent experts convene to share and compare their experiences with the goal of optimizing treatments for patients suffering from more than one of these common disorders. Over the years, the areas of obesity, diabetes, and hypertension have experienced an enormous expansion in clinical and basic data as well as tremendous growth in related technologies. Such growth has fueled a greater need to debate the many controversial issues and crystallize them into clinical conclusions. The CODHy Congress provides a forum to discuss and debate unresolved controversies, by allowing leading speakers ample time to present conflicts and their effects on patients, and the participating audience sufficient time to discuss and propose informed views. The Congress' goal is to provide answers to difficult controversial questions, allowing clinician to return to his practice with reliable, up-to-date scientific answers, based on the best existing evidence and expert opinion. |
